Pharma pay the lesser of 50-100% premium to share price and 3-5 peak revenue multiple?
there is an obvious disconnect between potential value and share price. It’s the boards job to close the valuation gap.
IMO part of this is data driven, execution and strategy. Once validated CPaCS in the client the strategy needs to focus on RC220 as a platform opportunity and clearly outline critical pathway to commercialisation. Currently a little hazy even though we can make our best efforts to speculate.
Investors don’t like uncertainty so it will be good to see what eventuates after P1 data becomes available. Seems like things are just getting started and a lot of hard work still to be done.
Add to My Watchlist
What is My Watchlist?
